Latham & Watkins Advises Sistema on its Acquisition of an Equity Interest in OBL Pharm

High profile transaction aims to create a leading Russian pharmaceuticals group.

January 18, 2019

Sistema PJSFC, a publicly traded diversified Russian holding company, has acquired an equity interest in JSC Pharmaceutical Enterprise Obolenskoe (OBL Pharm), a leading Russian pharmaceutical company. The stake was acquired jointly with VTB Bank and members of the OBL Pharm management team. The investment consortium collectively acquired 95.14% of OBL Pharm for a total investment of RUB15.5 billion. The transaction represents a milestone in the creation of a major Russian pharmaceuticals group. 

Latham & Watkins advised Sistema in the transaction with a Moscow team led by corporate partner Olga Ponomarenko with associates Timur Bayramov, Ivan Alaev, Vladimir Mikhailovsky, and Bairta Ochirova.

 

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.